DBV Technologies Announces Creation of US Subsidiary and Appoints Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & Strategy

        Print
| Source: DBV Technologies

BAGNEUX, France, April 7, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, today announced that it has established a US subsidiary, DBV Technologies Inc., in order to conduct operations in the United States, and that it appointed Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & Strategy.

DBV's core clinical activities are largely focused in the US, with the majority of the Company's most advanced trial, VIPES in peanut allergic patients, centers located in North America. The creation of DBV Technologies Inc. is part of a strategic decision to expand operations in the United States, a major market for the Company's core products.

"The opening of a US subsidiary is a major step forward for DBV. While preparing the entry of Viaskin Peanut into phase III, our goal is to continue to increase our visibility in the medical and investment communities, as well as continue to strengthen our commitment to our patients in the US" said Pierre-Henri Benhamou, Chief Executive Officer of DBV Technologies.

DBV Technologies Inc.'s first employee, Ms. Mesa, will be responsible for developing and implementing DBV's investor relations and strategy in the United States, and she will report to the Company's Chief Financial Officer David Schilansky. Ms. Mesa will also be a member of the Directors' Committee.

"We are very pleased to have Susanna join us as she is truly passionate about our Company's mission and commitment to serve our shareholders. Her in-depth knowledge of the markets and ability to communicate effectively with the investment community will be crucial to DBV's efforts to strengthen its presence in the United States" said David Schilansky, Chief Financial Officer of DBV Technologies.

Ms. Mesa joins DBV Technologies from the Trout Group, a leading investor relations and strategic advisory firm serving the life sciences and clean technology industries. During her time at Trout, Ms. Mesa focused on expanding clients' shareholder base and increasing exposure to investors, while also serving as an advisor on capital formation and business development opportunities. Prior to joining Trout in 2012, Ms. Mesa worked for the Corporate Development arm at the Leukemia and Lymphoma Society and at the Jefferies equity sales team. She graduated Magna Cum Laude from the University of Georgia in Athens.

About DBV Technologies

DBV Technologies is opening up a decisive new approach to the treatment of allergy - a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy - a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).
For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

CAUTION: Viaskin® is not approved for sale in the USA.

DBV Technologies Contacts

David Schilansky

Chief Financial Officer

Tel. : +33(0)1 55 42 78 75

david.schilansky@dbv-technologies.com
   
Susanna Mesa

VP Finance, US Investor Relations & Strategy

Tel. : +33(0)1 55 42 78 78

susanna.mesa@dbv-technologies.com

DBVDBV IR and Media Contacts
Nathalie Donne

Director, Business Development & Corporate Communications

Tel. : +33(0)1 55 42 78 72

nathalie.donne@dbv-technologies.com
 
Alan S. Roemer

U.S. Investor Relations

The Trout Group

Tel. : +1 646 378-2945

aroemer@troutgroup.com
BMC Communications

Media Relations

Brad Miles

Tel. : +1 646-513-3125

brad@bmccommunications.com
 

DBV Technologies Announces Creation of US Subsidiary http://hugin.info/156437/R/1774766/605064.pdf

HUG#1774766